BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

SALVAT has Completed Patient Enrollment in a Dose Finding Phase II Trial of SVT-40776


10/10/2007 7:34:36 AM

BARCELONA, Spain, October 9 /PRNewswire/ -- This double-blind, placebo-controlled and multi-center Phase II trial includes 332 patients with Overactive Bladder (OAB) and has been conducted at 77 sites in 11 countries (US, Germany, Spain, The Netherlands, Czech Republic, Hungary, Poland, Russia, South Africa, New Zealand and Australia). The company expects to report the results of this trial during November.

The total study treatment duration after screening and baseline has been 4 weeks. Patients have been randomized into one of five treatment arms, which include one placebo, one active control (Tolterodine, 4 mg once daily) and three SVT-40776 groups (once daily administration). The primary endpoint of the trial is the mean change from baseline to last day of treatment in the number of micturitions per day. The trial will also generate tolerability data.

"The successful completion of patient enrollment in this clinical trial represents an important milestone in the development of SVT-40776" said Jordi Julve, CEO.

"We are very excited to look at the data regarding the efficacy and safety of SVT-40776 and to confirm the excellent profile suggested by our previous clinical data. We expect that SVT-40776 will improve the efficacy/tolerability ratio compared to the current available treatments, being the treatment of choice for patients with OAB" continued Mr. Julve.

About SVT-40776

SVT-40776 is a new potent and selective M3 muscarinic antagonist for the treatment of OAB with high bladder/salivary gland selectivity, long half life and low metabolic rate. Compared to oxybutynin, tolterodine, solifenacin and darifenacin, SVT-40776 is the most potent and selective M3 vs M2 yet developed. This profile is expected to give SVT-40776 an improved efficacy and tolerability, increasing the benefit/risk ratio.

About SALVAT

SALVAT is an independent, privately owned, Spanish pharmaceutical group closely identified with technological innovation and strongly committed to R&D. In 2006 SALVAT's products were distributed in more than 30 countries all over the world in collaboration with well reputed pharmaceutical partners. SALVAT is working to strengthen its international presence by licensing its own developments, e.g. CETRAXAL eardrops (currently under US-FDA review) and by emphasizing collaborations regarding its pipeline products.

cviayna@salvatbiotech.comhttp://www.salvatbiotech.com

CONTACT: Contact: Cristina Viayna, Business Development & Licensing,
cviayna@salvatbiotech.com



Read at BioSpace.com

SALVAT
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES